PTN Palatin Technologies Inc.

+0.05  (+6%)
Previous Close 0.88
Open 0.88
Price To Book 13.3
Market Cap 200,661,287
Shares 215,556,222
Volume 1,448,980
Short Ratio 11.28
Av. Daily Volume 3,861,571

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced June 21, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Phase 2 trial to commence 1H 2019.
Heart failure
Phase 2 trial to commence 4Q 2019.
Non-infectious uveitis
Phase 2 trial to commence 1Q 2020.
Ulcerative colitis

Latest News

  1. Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
  2. Palatin (PTN) Stock Sinks As Market Gains: What You Should Know
  3. Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?
  4. Palatin Technologies To Present At Canaccord Genuity's 39th Annual Growth Conference
  5. Palatin (PTN) Gains As Market Dips: What You Should Know
  6. Should You Worry About Palatin Technologies, Inc.'s (NYSEMKT:PTN) CEO Pay Cheque?
  7. Palatin Technologies Provides Mid-Calendar Year Corporate Update
  8. Why Palatin Technologies Stock Dropped as Much as 21.5% Today
  9. Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
  10. Companies to Watch: Spotify downgraded, FDA signs off on Palatin drug, FedEx cuts prices
  11. Palatin's stock rockets after FDA OK to market sexual desire disorder treatment
  12. AMAG stock rallies on FDA approval for drug to increase women's sex drive
  13. FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
  14. FDA approves drug for loss of female sexual desire
  15. Edited Transcript of PTN earnings conference call or presentation 9-May-19 3:00pm GMT
  16. What Does Poltronic S.A.'s (WSE:PTN) Balance Sheet Tell Us About It?
  17. Palatin Technologies (PTN) Q3 2019 Earnings Call Transcript
  18. Palatin Technologies, Inc. to Host Earnings Call